Search

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more

Addressing the bureaucracy challenge

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

Dates: August 28-30, 2020 
Location: Riga, Latvia
Chairs: S Eichinger (EHA) & S Lejniece (LASH)

After a successful first edition, EHA is once again collaborating with the Latvian Society of Hematology (LASH), the Estonian Society of Hematology (EHS) and the Lithuanian Society of Hematology…

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

EHA-SWG Scientific Meeting on Aging and Hematology

Dates: October 12-14, 2018
Location: Warsaw, Poland
Chair: D Bron

Organized by:
EHA & the EHA Scientific Working Group on Aging and Hematology

Organizing committee:

D Bron, Institut Jules Bordet, Brussels, Belgium
L Adès, Hopital Saint Louis, Paris, France
R Cordoba, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
T Fulöp, Université…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more